Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Liquidia Corporation Common Stock (LQDA) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
Liquidia Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Liquidia Corporation Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.92 (market cap $42.21B), while Liquidia Corporation Common Stock trades at $34 (market cap $3.04B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 13.9× Liquidia Corporation Common Stock's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.05% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 3 Days and Liquidia Corporation Common Stock for 0 Days on average.

HLNLQDA
Market Cap
$42.21B$3.04B
Volume
13,841,86421,111,778
Sector
HealthHealth
52-Week High
$11.27$91.03
52-Week Low
$8.70$22.02
Typical Hold Time
3 Days0 Days
Enterprise Value
$52.02B$2.94B
Dividend Yield
2.05%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.

The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.

Liquidia Corporation Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN

No sentiment data available yet.

LQDA
62% Buy38% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.

Read more on LQDA →